文献速递临床试验与 GCP

全火麻仁蛋白及火麻仁蛋白水解物降血压的双盲随机交叉试验方案

A double-blind, randomized, crossover trial protocol of whole hemp seed protein and hemp seed protein hydrolysate consumption for hypertension.
PubMed 文献 · Trials · 2020-04-23

该试验为双盲随机交叉设计,纳入35名18-75岁高血压患者,比较酪蛋白、火麻仁蛋白及火麻仁蛋白加水解物对24小时收缩压的影响。试验周期22周,分三个6周治疗期,期间设2周洗脱期。主要结局为24小时收缩压,旨在评估火麻仁蛋白的降压潜力。

要点

  • 火麻仁蛋白及水解物每日两次,每次25克,与酪蛋白对照。
  • 主要结局为24小时收缩压,于第一治疗期首日及每期末日测量。
  • 纳入标准:收缩压130-160 mmHg且舒张压≤110 mmHg。

核心结论

  • 该试验旨在评估全火麻仁蛋白及火麻仁蛋白加水解物相较于酪蛋白的降压潜力,为首次在人体中探究膳食火麻蛋白加生物活性肽抗高血压益处的试验。

研究设计与样本

  • 随机、双盲、交叉临床试验,纳入35名18-75岁高血压患者,BMI 18.5-40 kg/m2,收缩压130-160 mmHg且舒张压≤110 mmHg。
  • 试验周期22周,含三个6周治疗期,期间设2周洗脱期,治疗每日两次,分别为25克酪蛋白、火麻仁蛋白或火麻仁蛋白加水解物。
  • 主要结局为24小时收缩压,于第一治疗期首日及每期末日测量;办公室血压、脉搏波传导速度、增强指数及人体测量于每期首末日测定。

关键数值与推荐

  • 主要结局为24小时收缩压,测量时间点为第一治疗期首日及每期末日。
  • 办公室血压、脉搏波传导速度、增强指数及人体测量于每期首末日测定。
  • 体成分通过双能X线吸收法(DXA)于第一治疗期首日及每治疗期末2天内评估。
  • 血液样本于每治疗期首日和最后2天采集,尿液样本于第一治疗期首日及每期末日采集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary hypertension accounts for almost 95% of all cases of high blood pressure and is a major modifiable risk factor for cardiovascular diseases. Lifestyle interventions have been shown to prevent hypertension. One of the prominent potential therapeutic lifestyle strategies to prevent or manage hypertension is increasing dietary protein as a macronutrient or as bioactive peptides. An emerging plant-based protein source that may have anti-hypertensive properties is hemp seed. METHODS/DESIGN: A randomized, double-blind, crossover clinical trial will be conducted on 35 hypertensive participants aged 18-75 years, with a BMI between 18.5 and 40 kg/m2, systolic blood pressure (SBP) between 130 and 160 mmHg and diastolic blood pressure (DBP) ≤ 110 mmHg. The trial will be conducted for a period of 22 weeks and will consist of three treatment periods of 6 weeks, separated by 2-week washout periods. The treatments will be consumed twice a day and consist of 25 g casein, hemp seed protein (HSP), or HSP plus HSP hydrolysate (HSP+). The primary outcome of this trial is 24-h SBP, measured on the first day of first phase and the last day of each phase. Office-measured blood pressure, pulse-wave velocity and augmentation index and anthropometrics will be determined at the first and last days of each period. Also, body composition will be assessed by dual x-ray absorptiometry (DXA) scan on the first day of the first phase and within the last 2 days of each treatment period. Blood samples will be collected on the first and last 2 days of each treatment phase whereas urine samples will be collected on the first day of the first phase plus the last day of each phase to be analyzed for specific biomarkers. DISCUSSION: This trial protocol is designed to evaluate the hypotensive potential of consuming whole HSP, and HSP+, in comparison to casein protein. This study will be the first trial investigating the potential anti-hypertensive benefit of dietary hemp protein plus bioactive peptide consumption in humans. TRIAL REGISTRATION: National Clinical Trial (NCT), ID: NCT03508895. Registered on 28 June 2018. Retrospectively registered on the publicly accessible Registry Databank at ClinicalTrials.gov (http://ClinicalTrials.gov).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Samsamikor M, Mackay D, Mollard RC, et al. A double-blind, randomized, crossover trial protocol of whole hemp seed protein and hemp seed protein hydrolysate consumption for hypertension. Trials. 2020. PMID: 32326966. doi:10.1186/s13063-020-4164-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。